Sandbox sc: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:


* For children less than eight years of age
* For children less than eight years of age
:* Preferred regimen:
:* Preferred regimen: [[TMP/SMZ]] 8/40 mg/ kg/day bid orally administered for six weeks {{and}} [[Streptomycin]] 30 mg/kg/day once daily intramuscularly administered for three weeks {{or}} [[Gentamicin]] 5 mg/kg/day once daily intravenously or intramuscularly administered for 7-10 days
:* Alternative regimen:
:* Alternative regimen (1): [[TMP/SMZ]] {{and}} [[Rifampicin]] 15 mg/kg/day orally each administered for 6 weeks
 
:* Alternative regimen (2): [[Rifampicin]] {{and}} an [[Aminoglycoside]]


===Ehrlichiosis===
===Ehrlichiosis===

Revision as of 19:42, 16 June 2015

Anaplasmosis

  • Human granulocytic anaplasmosis, suspected or symptomatic [1]
  • Preferred regimen: Doxycycline 100 mg orally bid (or intravenously for those patients unable to take an oral medication) for 10 days
  • Alternative regimen: Rifampin 300 mg orally bid for 7–10 days (For patients with mild illness due to HGA who are not optimally suited for doxycycline treatment because of a history of drug allergy, pregnancy, or age <8 years)
  • Pediatric regimen: Doxycycline 4 mg/kg per day in 2 divided doses (maximum of 100 mg per dose) given orally (or intravenously for children unable to take an oral medication); Rifampin 10 mg/kg bid for children (maximum of 300 mg per dose) (For children age <8 years without Lyme disease)
NOTE (1): Children ≥8 years of age may be treated with a 10-day course of Doxycycline; For severely ill children <8 years of age without concomitant Lyme disease, the panel recommended an abbreviated treatment course of 4–5 days
NOTE (2): If the patient has concomitant Lyme disease, then Amoxicillin 50 mg/kg per day in 3 divided doses (maximum of 500 mg per dose) OR Cefuroxime axetil 30 mg/kg per day in 2 divided doses (maximum of 500 mg per dose) should be initiated at the conclusion of the course of Doxycycline to complete a 14-day total course of antibiotic therapy
NOTE: Rifampin is not effective therapy for Lyme disease, patients coinfected with B. burgdorferi should also be treated with Amoxicillin OR Cefuroxime axetil

Brucellosis

  • Uncomplicated brucellosis in adults and children eight years of age and older
  • Preferred regimen: Doxycycline 100 mg bid for six weeks OR Tetracycline 500 mg every six hours orally administered for at least six weeks
  • NOTE: Streptomycin 1 g/day intramuscularly administered for the first two to three weeks of therapy OR Gentamicin 5mg/kg/day intravenously or intramuscularly for 7-10 days in combination with Doxycycline administered for six weeks
  • Alternative regimen (1): Doxycycline 200 mg/day orally AND Rifampicin 600–900 mg/day orally, both drugs administered for six weeks
  • Alternative regimen (2): Fluoroquinolones
  • NTOE: Quinolones should always be used in combination with other drugs, such as Doxycycline or Rifampicin
  • Alternative regimen (3): TMP/SMZ in a fixed ratio of 1:5 (80 mg TMP/400 mg SMZ)
  • NOTE: TMP/SMZ should always be used in combination with another agent, such as Doxycycline, Rifampicin or Streptomycin
  • Complications of brucellosis
  • Spondylitis
  • Preferred regimen: Continuation of Doxycycline for eight weeks or more; Surgical drainage is rarely necessary.
  • Neurobrucellosis
  • Brucella endocarditis
  • For children less than eight years of age
  • Preferred regimen: TMP/SMZ 8/40 mg/ kg/day bid orally administered for six weeks AND Streptomycin 30 mg/kg/day once daily intramuscularly administered for three weeks OR Gentamicin 5 mg/kg/day once daily intravenously or intramuscularly administered for 7-10 days
  • Alternative regimen (1): TMP/SMZ AND Rifampicin 15 mg/kg/day orally each administered for 6 weeks

Ehrlichiosis

Tularemia

Typhoid fever

References

  1. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.